GSC
REGN icon

Ground Swell Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Ground Swell Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,021
Closed -$574K – 159
2025
Q3 		$574K Buy
+1,021
New +$577K 1.26% 21
2022
Q4 		– Sell
-321
Closed -$221K – 133
2022
Q3 		$221K Sell
321
-292
-48% -$184K 0.63% 48
2022
Q2 		$362K Buy
+613
New +$398K 0.66% 47
2021
Q3 		– Sell
-561
Closed -$313K – 118
2021
Q2 		$313K Sell
561
-142
-20% -$71.9K 1.49% 14
2021
Q1 		$333K Buy
+703
New +$342K 1.08% 22
2014
Q3 		– Sell
-94
Closed -$27K – 2700
2014
Q2 		$27K Buy
+94
New +$27.9K 0.05% 303

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ground Swell Capital's REGN Position: Q4 2025 in Review

Ground Swell Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 1,021 shares — an estimated $574K sold.

Ground Swell Capital first reported a position in REGN in Q2 2014 and held it in 6 quarters. The position peaked at $574K in Q3 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Ground Swell Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ground Swell Capital sold 1,021 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $574K.
  • Ground Swell Capital first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 6 quarters.
  • Ground Swell Capital's Regeneron Pharmaceuticals position peaked at $574K in Q3 2025.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Ground Swell Capital's 13F filing for Q4 2025, filed 4 Feb 2026.